Check-Point Inhibitors before and after Allogeneic Hematopoietic Stem Cell Transplant: The Double-Edge Sword
Co-inhibitory signaling pathways play a pivotal role in hampering immune responses in cancer patients, enabling tumor escape. In hematologic malignancies, allogeneic hematopoietic stem cell transplantation (allo-HSCT) was the first immunotherapy to demonstrate clinical efficacy with a potential to cure. More recently, clinical trials with antibodies targeting both the PD-1 and CTLA-4 pathways demonstrated efficacy, with durable remissions in a proportion of patients, in a variety of solid tumors, and more recently in hematologic malignancies [1].
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Betul Oran, Naval Daver Source Type: research
More News: Biology | Cancer | Cancer & Oncology | Clinical Trials | Hematology | Immunotherapy | Stem Cell Therapy | Stem Cells | Transplants